Has Christopher Burkeen, MD received payments from drug or device companies?

Yes. Drug and device makers reported $260,610 in general payments to Christopher Burkeen, MD across 628 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Christopher Burkeen, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Christopher Burkeen, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Christopher Burkeen, MD

Hematology & Oncology · Lexington, KYNPI 1225490253

Payments from drug & device makers

$260,610in general payments, 2019–2025

Across 628 payments — averaging $414.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$205K
Biontech SE$44K
Merck$916
Novartis$826
Johnson & Johnson$763
Daiichi Sankyo Inc.$760
plus $8K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca(2 entities)	45	$204,883
Biontech SE	13	$43,872
Merck	51	$916
Novartis	45	$826
Johnson & Johnson	43	$763
Daiichi Sankyo Inc.	27	$760
Pfizer	36	$632
Incyte Corporation	19	$549
E.r. Squibb & Sons, L.L.C.	30	$497
Gilead(2 entities)	22	$491
Genentech USA, Inc.	21	$405
Eisai Inc.	15	$371
Regeneron Healthcare Solutions, Inc.	10	$326
Takeda Pharmaceuticals U.S.A., Inc.	13	$315
GSK	12	$311
AbbVie	15	$301
Bristol Myers Squibb	15	$293
Seagen Inc.	7	$264
Pharmacyclics LLC, An Abbvie Company	5	$226
Beigene USA, Inc.	6	$209
Stemline Therapeutics Inc.	10	$189
Sanofi	8	$168
Puma Biotechnology, Inc.	9	$163
AVEO Pharmaceuticals, Inc.	10	$155
Array Biopharma Inc	11	$143
EMD Serono, Inc.	6	$142
Bayer	8	$131
Tersera Therapeutics LLC	6	$120
Geron Corporation	3	$109
Sumitomo Pharma America, Inc.	6	$104
Coherus Oncology, Inc.	5	$100
Janssen Scientific Affairs, LLC	3	$99
Astellas Pharma US Inc	6	$97
Lilly USA, LLC	5	$94
Genmab U.S., Inc.	4	$88
Beone Medicines USA, Inc.	3	$88
Rigel Pharmaceuticals, Inc.	5	$82
Ipsen Biopharmaceuticals, Inc	4	$82
Blueprint Medicines Corporation	3	$78
Boehringer Ingelheim	3	$74
Exelixis Inc.	5	$71
Taiho Oncology, Inc.	3	$69
Sun Pharmaceutical Industries Inc.	3	$67
Mirati Therapeutics, Inc.	4	$66
ADC Therapeutics America, Inc.	4	$65
Amgen	3	$60
Sobi, Inc	3	$53
Morphosys, US Inc.	3	$50
Pharmaessentia USA Corporation	2	$45
Fennec Pharmaceuticals, Inc.	3	$44
Springworks Therapeutics, Inc.	2	$39
Kyowa Kirin, Inc.	2	$36
G1 Therapeutics, Inc.	2	$34
Tempus AI, Inc	1	$30
Alnylam Pharmaceuticals Inc.	1	$30
Progenics Pharmaceuticals, Inc.	1	$24
Jazz Pharmaceuticals Inc.	1	$24
Cumberland Pharmaceuticals, Inc.	1	$23
Accord Healthcare, Inc.	1	$23
Fresenius Kabi USA, LLC	1	$20

How this compares

$260,610 in reported general payments places this provider in the 75th percentile of 143 hematology & oncology providers in Kentucky.

See all hematology & oncology providers in Kentucky →

Medicare billing

Part B allowed, 2024

$146,219

Medicare patients

422

Services billed

2,058

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Lexington

Firas BadinLexington$6.7M
John VillanoLexington$3.2M
Nicola JabbourLexington$568K
Amy SchellLexington$556K
Chaitanya IragavarapuLexington$488K
Jessica CroleyLexington$272K
Mara ChambersLexington$179K
Ayman QasrawiLexington$125K
Roger FleischmanLexington$108K
Lee HicksLexington$91K

See the full list for Kentucky →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →